The quest for biomarkers in IBS-where should it lead us?

Neurogastroenterology and Motility

Volumn 26, Issue 12, 2014, Pages 1669-1676

  Corsetti, M ^a   Van Oudenhove, L ^a   Tack, J ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Biomarkers; IBS; Positive diagnosis; Treatment effect

Indexed keywords

BIOLOGICAL MARKER;

HUMAN; IRRITABLE BOWEL SYNDROME;

BIOLOGICAL MARKERS; HUMANS; IRRITABLE BOWEL SYNDROME;

EID: 84911490857     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/nmo.12475     Document Type: Review

References (54)

1. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006; 130: 1480-91.
2. Cremonini F, Talley NJ. Irritable bowel syndrome: epidemiology, natural history, health care seeking and emerging risk factors. Gastroenterol Clin North Am 2005; 34: 189-204.
3. Canavan C, West J, Card T. Review article: the economic impact of the irritable bowel syndrome. Aliment Pharmacol Ther 2014; 40: 1023-34.
4. Camilleri M, Lasch K, Zhou W. Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2012; 303: G775-85.
5. Ford AC, Bercik P, Morgan DG, Bolino C, Pintos-Sanchez MI, Moayyedi P. Validation of the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care. Gastroenterology 2013; 145: 1262-70.
6. Sood R, Law GR, Ford AC. Diagnosis of IBS: symptoms, symptom-based criteria, biomarkers or 'psychomarkers'? Nat Rev Gastroenterol Hepatol 2014; 11: 683-91.
7. Shivaji UN, Ford AC. Beliefs about management of irritable bowel syndrome in primary care: cross-sectional survey in one locality. Prim Health Care Res Dev. 2014; 7: 1-7.
8. Spiller RC. Potential biomarkers. Gastroenterol Clin North Am 2011; 40: 121-39.
9. Chaudhary NA, Truelove SC. Human colonic motility. A comparative study of normal subjects, patients with ulcerative colitis, and patients with the irritable colon syndrome. Gastroenterology 1968; 54(Suppl): 777-8.
10. Kellow JE, Bennett E. Functional disorders of the small intestine. Semin Gastrointest Dis 1996; 7: 208-16.
11. Camilleri M. Motor function in irritable bowel syndrome. Can J Gastroenterol 1999; 13(Suppl. A): 8A-11A.
12. Spiegel B, Bolus R, Harris LA, Lucak S, Naliboff B, Esrailian E, Chey WD, Lembo A et al. Measuring irritable bowel syndrome patient-reported outcomes with an abdominal pain numeric rating scale. Aliment Pharmacol Ther 2009; 30: 1159-70.
13. Penning C, Gielkens HA, Hemelaar M, Lamers CB, Masclee AA. Reproducibility of antroduodenal motility during prolonged ambulatory recording. Neurogastroenterol Motil 2001; 13: 133-41.
14. Rao SS, Singh S, Mudipalli R. Day-to-day reproducibility of prolonged ambulatory colonic manometry in healthy subjects. Neurogastroenterol Motil 2010; 22: 640-e178.
15. Di Stefano M, Miceli E, Missanelli A, Mazzocchi S, Corazza GR. Meal induced rectosigmoid tone modification: a low caloric meal accurately separates functional and organic gastrointestinal disease patients. Gut 2006; 55: 1409-14.
16. Steens J, Van Der Schaar PJ, Penning C, Brussee J, Masclee AA. Compliance, tone and sensitivity of the rectum in different subtypes of irritable bowel syndrome. Neurogastroenterol Motil 2002; 14: 241-7.
17. Zar S, Benson MJ, Kumar D. Rectal afferent hypersensitivity and compliance in irritable bowel syndrome: differences between diarrhoea-predominant and constipation-predominant subgroups. Eur J Gastroenterol Hepatol 2006; 18: 151-8.
18. Törnblom H, Van Oudenhove L, Tack J, Simrén M. Interaction between preprandial and postprandial rectal sensory and motor abnormalities in IBS. Gut 2014; 63: 1441-9.
19. Odunsi ST, Camilleri M, Bharucha AE, Papathanasopoulos A, Busciglio I, Burton D, Zinsmeister AR. Reproducibility and performance characteristics of colonic compliance, tone, and sensory tests in healthy humans. Dig Dis Sci 2010; 55: 709-15.
20. Hammer HF, Phillips SF, Camilleri M, Hanson RB. Rectal tone, distensibility, and perception: reproducibility and response to different distensions. Am J Physiol 1998; 274(3 Pt 1): G584-90.
21. Cremonini F, Houghton LA, Camilleri M, Ferber I, Fell C, Cox V, Castillo EJ, Alpers DH et al. Barostat testing of rectal sensation and compliance in humans: comparison of results across two centres and overall reproducibility. Neurogastroenterol Motil 2005; 17: 810-20.
22. Degen LP, Phillips SF. How well does stool form reflect colonic transit? Gut 1996; 39: 109-13.
23. 3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers. Aliment Pharmacol Ther 2000; 14: 775-82.
24. Emmanuel AV, Kamm MA, Roy AJ, Antonelli K. Effect of a novel prokinetic drug, R093877, on gastrointestinal transit in healthy volunteers. Gut 1998; 42: 511-6.
25. Metcalf AM, Phillips SF, Zinsmeister AR, MacCarty RL, Beart RW, Wolff BG. Simplified assessment of segmental colonic transit. Gastroenterology 1987; 92: 40-7.
26. Charles F, Camilleri M, Phillips SF, Thomforde GM, Forstrom LA. Scintigraphy of the whole gut: clinical evaluation of transit disorders. Mayo Clin Proc 1995; 70: 113-8.
27. Deiteren A, Camilleri M, Bharucha AE, Burton D, McKinzie S, Rao AS, Zinsmeister AR. Performance characteristics of scintigraphic colon transit measurement in health and irritable bowel syndrome and relationship to bowel functions. Neurogastroenterol Motil 2010; 22: 415-23.
28. Camilleri M, McKinzie S, Busciglio I, Low PA, Sweetser S, Burton D, Baxter K, Ryks M, Zinsmeister AR. Prospective study of motor, sensory, psychologic, and autonomic functions in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2008; 6: 772-81.
29. Törnblom H, Van Oudenhove L, Sadik R, Abrahamsson H, Tack J, Simrén M. Colonic transit time and IBS symptoms: what's the link? Am J Gastroenterol 2012; 107: 754-60.
30. Camilleri M. Scintigraphic biomarkers for colonic dysmotility. Clin Pharmacol Ther 2010; 87: 748-53.
31. Camilleri M, Shin A, Busciglio I, Carlson P, Acosta A, Bharucha AE, Burton D, Lamsam J et al. Validating biomarkers of treatable mechanisms in irritable bowel syndrome. Neurogastroenterol Motil 2014; 26: 1677-85.
32. Mertz H, Naliboff B, Munakata J, Niazi N, Mayer EA. Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology 1995; 109: 40-52.
33. Corsetti M, Cesana B, Bhoori S, Basilisco G. Rectal hyperreactivity to distention in patients with irritable bowel syndrome: role of distention rate. Clin Gastroenterol Hepatol 2004; 2: 49-56.
34. Bouin M, Plourde V, Boivin M, Riberdy M, Lupien F, Laganière M, Verrier P, Poitras P. Rectal distention testing in patients with irritable bowel syndrome: sensitivity, specificity, and predictive values of pain sensory thresholds. Gastroenterology 2002; 122: 1771-7.
35. Ludidi S, Conchillo JM, Keszthelyi D, Van Avesaat M, Kruimel JW, Jonkers DM, Masclee AA. Rectal hypersensitivity as hallmark for irritable bowel syndrome: defining the optimal cutoff. Neurogastroenterol Motil 2012; 24: 729-33.
36. Posserud I, Syrous A, Lindström L, Tack J, Abrahamsson H, Simrén M. Altered rectal perception in irritable bowel syndrome is associated with symptom severity. Gastroenterology 2007; 133: 1113-23.
37. Naliboff BD, Berman S, Suyenobu B, Labus JS, Chang L, Stains J, Mandelkern MA, Mayer EA. Longitudinal change in perceptual and brain activation response to visceral stimuli in irritable bowel syndrome patients. Gastroenterology 2006; 131: 352-65.
38. Nan J, Liu J, Li G, Xiong S, Yan X, Yin Q, Zeng F, von Deneen KM et al. Whole-Brain Functional Connectivity Identification of Functional Dyspepsia. PLoS ONE 2013; 8: e65870.
39. Labus JS, Van Horn JD, Torgerson C, Gupta A, Ashe-McNalley C, Liu C, Naliboff BD, Tillisch K et al. Architecture of anatomical brain networks differs in irritable bowel syndrome compared to healthy controls. Gastroenterology 2014; 146: S-109.
40. Mayberg HS. Targeted electrode-based modulation of neural circuits for depression. J Clin Invest 2009; 119: 717-25.
41. 3 receptor antagonist: a pilot study. Aliment Pharmacol Ther 2008; 28: 344-52.
42. Lembo AJ, Neri B, Tolley J, Barken D, Carroll S, Pan H. Use of serum biomarkers in a diagnostic test for irritable bowel syndrome. Aliment Pharmacol Ther 2009; 29: 834-42.
43. Jones MP, Chey WD, Singh S, Gong H, Shringarpure R, Hoe N, Chuang E, Talley NJ. A biomarker panel and psychological morbidity differentiates the irritable bowel syndrome from health and provides novel pathophysiological leads. Aliment Pharmacol Ther 2014; 39: 426-37.
44. Waugh N, Cummins E, Royle P, Kandala NB, Shyangdan D, Arasaradnam R, Clar C, Johnston R. Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation. Health Technol Assess 2013; 17: xv-xix, 1-211. doi: 10.3310/hta17550.
45. Ohman L, Stridsberg M, Isaksson S, Jerlstad P, Simrén M. Altered levels of fecal chromogranins and secretogranins in IBS: relevance for pathophysiology and symptoms? Am J Gastroenterol 2012; 107: 440-7.
46. Gecse K, Róka R, Ferrier L, Leveque M, Eutamene H, Cartier C, Ait-Belgnaoui A, Rosztóczy A et al. Increased faecal serine protease activity in diarrhoeic IBS patients: a colonic lumenal factor impairing colonic permeability and sensitivity. Gut 2008; 57: 591-9.
47. Tooth D, Garsed K, Singh G, Marciani L, Lam C, Fordham I, Fields A, Banwait R et al. Characterisation of faecal protease activity in irritable bowel syndrome with diarrhoea: origin and effect of gut transit. Gut 2014; 63: 753-60.
48. Wedlake L, A'Hern R, Russell D, Thomas K, Walters JR, Andreyev HJ. Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2009; 30: 707-17.
49. Bajor A, Törnblom H, Rudling M, Ung KA, Simrén M. Increased colonic bile acid exposure: a relevant factor for symptoms and treatment in IBS. Gut. 2014. doi: 10.1136/gutjnl-2013-305965. [Epub 2014 Apr 12]
50. Ford AC, Talley NJ. Mucosal inflammation as a potential etiological factor in irritable bowel syndrome: a systematic review. J Gastroenterol 2011; 46: 421-31.
51. Hughes PA, Zola H, Penttila IA, Blackshaw LA, Andrews JM, Krumbiegel D. Immune activation in irritable bowel syndrome: can neuroimmune interactions explain symptoms? Am J Gastroenterol 2013; 108: 1066-74.
52. Doyle LA, Sepehr GJ, Hamilton MJ, Akin C, Castells MC, Hornick JL. A clinicopathologic study of 24 cases of systemic mastocytosis involving the gastrointestinal tract and assessment of mucosal mast cell density in irritable bowel syndrome and asymptomatic patients. Am J Surg Pathol 2014; 38: 832-43.
53. Vicario M, González-Castro AM, Martínez C, Lobo B, Pigrau M, Guilarte M, de Torres I, Mosquera JL et al. Increased humoral immunity in the jejunum of diarrhoea-predominant irritable bowel syndrome associated with clinical manifestations. Gut 2014. doi: 10.1136/gutjnl-2013-306236. [Epub 2014 Sept 10]
54. Vazquez-Roque MI, Camilleri M, Smyrk T, Murray JA, Marietta E, O'Neill J, Carlson P, Lamsam J et al. A controlled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: effects on bowel frequency and intestinal function. Gastroenterology 2013; 144: 903-11.